Literature DB >> 24118110

Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?

Hyuk Yoon1, Dong Ho Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, Kyu Keun Kang, Dong Hyun Oh, Dong Kee Jang, Jun-Won Chung.   

Abstract

BACKGROUND AND AIM: Although several meta-analyses suggested that sequential therapy (SQT) is superior to standard triple therapy (STT) for the eradication of Helicobacter pylori, these results were mainly based on the studies from Italy. The aim of this study was to assess the efficacy of 10-day SQT for H. pylori infection compared with STT in Asian adults.
METHODS: We performed an electronic search of the Cochrane Library, Medline, and Embase up to April 21, 2013, with no language restrictions. Randomized controlled trials comparing 10-day SQT with STT for H. pylori eradication in Asian adults were included in this analysis. The primary outcome measures were the risk ratios (RRs) for successful eradication of H. pylori based on intention to treat comparing SQT with STT. The secondary outcome measures were the RRs for side effects.
RESULTS: Seventeen randomized controlled trials with a total of 3419 participants (1591 for SQT and 1828 for STT) met the inclusion criteria. The eradication rate was 81.8% (95% CI: 78.9-84.6) for SQT and 74.3% (95% CI: 69.6-78.8) for SST, respectively. The pooled RR was 1.10 (95% CI: 1.04-1.16, P = 0.0005), which demonstrated significant superiority of SQT over STT, and the number needed to treat was 14 (95% CI: 9-29). There were no significant differences between SQT and STT in the risk of side effects (the pooled RR: 0.98, 95% CI: 0.87-1.10, P = 0.73).
CONCLUSION: Ten-day SQT appears to be superior to STT for H. pylori eradication in Asian adults. However, the pooled efficacy is lower than results from earlier European studies.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Helicobacter pylori; eradication; meta-analysis; sequential therapy

Mesh:

Substances:

Year:  2013        PMID: 24118110     DOI: 10.1111/jgh.12397

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  19 in total

Review 1.  Current Helicobacter pylori treatment in 2014.

Authors:  Fatih Ermis; Elif Senocak Tasci
Journal:  World J Methodol       Date:  2015-06-26

2.  Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance.

Authors:  Colin W Howden; William D Chey; Nimish B Vakil
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

Review 3.  Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.

Authors:  Vasilios Papastergiou; Sotirios D Georgopoulos; Stylianos Karatapanis
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.

Authors:  Can Dolapcioglu; Aysun Koc-Yesiltoprak; Emel Ahishali; Aziz Kural; Hatice Dolapcioglu; Aliye Soylu; Resat Dabak
Journal:  Int J Clin Exp Med       Date:  2014-08-15

5.  Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

6.  Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.

Authors:  Boram Han; Hyo Jung Kim; Ho-Young Yhim; Doyeun Oh; Sung Hwa Bae; Ho-Jin Shin; Won-Sik Lee; JiHyun Kwon; Jeong-Ok Lee; Hwa Jung Kim; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2022-05-28       Impact factor: 3.673

Review 7.  [Role of the gut microbiome in the pathogenesis and treatment of inflammatory bowel diseases].

Authors:  Jan Kempski; Samuel Huber
Journal:  Inn Med (Heidelb)       Date:  2022-08-31

Review 8.  Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis.

Authors:  Youhua Wang; Rulin Zhao; Ben Wang; Qiaoyun Zhao; Zhen Li; Liya Zhu-Ge; Wenzhu Yin; Yong Xie
Journal:  Eur J Clin Pharmacol       Date:  2017-10-08       Impact factor: 2.953

9.  Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?

Authors:  Anil John; Saad Al Kaabi; Sanjay Doiphode; Prem Chandra; Manik Sharma; Ragesh Babu; Rafie Yacoub; Moutaz Derbala
Journal:  Indian J Gastroenterol       Date:  2015-11-05

10.  Immunodominant epitope-specific Th1 but not Th17 responses mediate protection against Helicobacter pylori infection following UreB vaccination of BALB/c mice.

Authors:  Bin Li; Li Chen; Heqiang Sun; Wuchen Yang; Jian Hu; Yafei He; Shanshan Wei; Zhuo Zhao; Jinyong Zhang; Haibo Li; Quanming Zou; Chao Wu
Journal:  Sci Rep       Date:  2015-10-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.